IQVIA accelerates therapeutic innovation through 15+ Centers of Excellence spanning oncology, cardiology, CNS, infectious diseases, and rare diseases. Since 2016, IQVIA has helped develop 70%+ of all new FDA-approved drugs and supported ~80% of approvals for genetic disease therapies. Proven expertise includes 200+ cell and gene therapy trials in 70+ countries, recruitment of \~200K patients in 20+ cardiovascular outcomes trials, and involvement in 46 oncology approvals across 14 indications. All GLP-1 drug developments leveraged IQVIA’s services. With 4,400+ scientific publications in five years, IQVIA demonstrates unmatched impact on clinical development and scientific advancement.

Join for free to read